Analysts keep Moderate Buy on IDEXX Laboratories stock
Published on 10/06/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IDEXX Laboratories (ISIN US45168D1046) was at EUR 470.75 at Lang & Schwarz on October 6, 2026 at 12:49 p.m. CEST, up 0.24 percent versus the EUR 469.60 prior close. MarketBeat reported on October 5, 2026 that six of 10 analysts rate the company a Buy and four rate it a Hold, producing a Moderate Buy consensus.
Analysts see room above USD 747
The average 12-month analyst target stood at USD 747.00 in the MarketBeat report, compared with the reported opening price of USD 518.39. That target was 43.79 percent above the opening price, although it is a US dollar estimate and therefore is not a direct comparison with the euro reference price.
The same report showed a divided research picture. UBS and Citigroup had raised their targets to USD 670.00, while Barclays had cut its target from USD 800.00 to USD 710.00, with Barclays retaining an Overweight rating.
Second-quarter revenue beats consensus
MarketBeat said IDEXX reported USD 1.22 billion in revenue for the second quarter of 2026, versus USD 1.20 billion expected, a 1.67 percent beat against consensus. Revenue increased 9.70 percent from the same quarter a year earlier.
GAAP earnings per share reached USD 4.27 in the second quarter, above the USD 3.94 consensus and USD 3.50 recorded in the prior-year quarter. The company set fiscal 2026 earnings-per-share guidance at USD 14.69 to USD 14.94.
CoVetAI adds a software angle
On September 16, 2026, IDEXX announced the acquisition of CoVetAI, a provider of AI-based ambient listening and clinical workflow software for veterinary practices, according to MarketScreener. Financial terms were not disclosed.
The transaction connects IDEXX diagnostics, practice software and artificial intelligence tools. The cited release said more than 10,000 clinics use IDEXX cloud-based practice-management systems, giving the software strategy a measurable installed base.
Stock remains below its yearly high
IDEXX had a market capitalization of USD 41.6 billion as of October 6, 2026. Its 52-week range was USD 500.61 to USD 769.98, leaving the latest US quote below the yearly high while the company continues to show double-digit earnings-per-share guidance at the midpoint of its fiscal 2026 range.
The stock was trading at EUR 470.75 at Lang & Schwarz on October 6, 2026 at 12:49 p.m. CEST, plus 0.24 percent versus the prior close of EUR 469.60. The further course of trading is shown by the continuously updated real-time quote of IDEXX Laboratories stock.
IDEXX Laboratories stock facts
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- Ticker: IDXX
- Primary exchange: NASDAQ
- Price Lang & Schwarz as of October 6, 2026, 12:49 p.m. CEST: EUR 470.75
- Change versus prior close: plus 0.24 percent
- Prior close Lang & Schwarz October 5, 2026: EUR 469.60
- Market capitalization: USD 41.6 billion as of October 6, 2026
- 52-week range: USD 500.61-769.98
- Sector / Industry: Medical Equipment, Supplies & Distribution
- Index membership: S&P 500
